Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 200-Day Moving Average – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $11.03 and traded as low as $9.56. Astellas Pharma shares last traded at $9.65, with a volume of 324,152 shares trading hands.

Astellas Pharma Trading Down 1.7 %

The firm has a market capitalization of $17.46 billion, a P/E ratio of 45.95 and a beta of 0.33. The business’s 50 day moving average is $10.89 and its two-hundred day moving average is $11.03. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 EPS for the quarter. The company had revenue of $3.11 billion for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. Analysts expect that Astellas Pharma Inc. will post 0.61 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.